O GoConqr está de visual novo! Conte para nós o que você achou.

Registre-se grátis

Flashcards

Signalling

lucypickles Inglês 46 flashcards

Flashcards do conjunto (46)

  1. 1Examples of target proteins in a signalling pathway- metabolic enzymes
    - gene regulatory protein
    - cytoskeletal protein
  2. 2Types of receptors1) cell surface
    2) IC
    e.g. ion channel coupled receptors
    GPCRs
    Enzyme linked
  3. 3Synaptic signallingfast
    low affinity receptor
    high concentration of local ligand
  4. 4Endocrine signallingSlow
    high affinity receptor
    low concentration of local ligand
  5. 5Responses to ACh (heart muscle cell/salivary gland cell/skeletal muscle cell)Heart muscle - decreased rate and force of contraction
    Skeletal muscle - contraction
    Salivary gland - secretion
  6. 6Intracellular signalling complexes1) on scaffold protein
    2) on activated receptor
    3) on phosphoinositide docking sites
  7. 7EC domain of RTKsVaried
    e.g. cysteine-rich/fibronectin-like/immunoglobin-like
  8. 8RTK activationLigand dimerises and facilitates dimerisation of receptors.
    IC kinase domains cross-phosphorylate each other
  9. 9Analysis exploiting dimerisation1) inactivation of one IC domain will poison the other = dominant negative
    2) addition of homodimerisation domain will lead to constitutive activation
  10. 10HSPGs-multifunctional ECM components
    - Protein core (tethered/secreted/TM)
    - Sugar chains = modified mainly by sulfation (code that creates binding sites for specific protiens)
  11. 11What does SH2 bind to?1 binding site for phospho-tyrosine
    1 for amino acid (glutamic acid, glutamic acid, isoleucine)
  12. 12RAS activation-SH2 domain of GBR2 binds to docking sites
    -SH3 domain binds to SOS(GEF) and couples receptor to inactive RAS
    -SOS promotes GDP-dissociation from RAS leading to GTP binding and SOS dissociation
  13. 13FRET-2 fusion proteins are produces attaches to different coloured GFP so that excitation of the first protein will emit light that excites the second protein if they are close enough together. If emitted light corresponds to emission of seconds protein they are interacting
  14. 14Leprechaunsim-insulin receptor mutation
    - fatal in first 2yrs
    - low subcutaneous fat and muscle
    - abnormal skin
    -excess hair growth
  15. 15Rabson-Mendenall syndrome- insulin receptor mutations
    - survival to second decade
    - skin/teeth abnormality
    - hair overgrowth
    - pineal hyperplasia
  16. 16Type-A insulin resistanceSurvival to middle age
  17. 17Insulin productionMade in the B-cell of the pancreas and secreted to the bloodstream
    Requires a lot of processing from pro-insulin to insulin
  18. 18Immediate effects of insulinGlucose uptake from the blood to muscle cells and adipocytes
  19. 19Effects due to long-term exposureincreased expression of liver enzymes that synthesise glycogen and adipocyte enzymes that synthesise triacylglycerols
  20. 20Insulin receptoralpha (EC) and beta (TM and IC) subunits are initially formed as a single polypeptide and then cleaved
    Disulphide bonds hold the dimers together
  21. 21Receptor activation - RAS pathway- binding to the alpha subunit causes cross-phosphorylation of the IC kinases
    - the receptor then phosphorylates IRS which contains a phosphotyrosine domain (therefore binds to site on receptor)
    - IRS acts as a docking site for proteins e.g. GRB2 to activate RAS pathway
  22. 22PI3-kinase2 subunits - p85 (SH2 domain)
    p110 (kinase domain)
  23. 23RAS-independent signalling (inositol pathway)-PI3-Kinase binds to IPS and phosphorylates docking site on PKB (membrane bound phosphoinositol)
    At the membrane PKB is phosphorylated by kinases e.g. PKD1
    PKB undergos a confirmational change and becomes active
  24. 24PKB effectsphosphorylates GSK3 meaning glycogen synthesis increases (GSK3 inhibits glycogen synthesis)
    Causes Glut4 translocation to membrane
    PEPCK increases glycogen synthesis and is activated when FOXO binds to IRS. PKB inhibition of FOXO (phosphorylation) means PEPCK is inhibited
  25. 25How do we know the exact mechanism of regulation for some targets?Promoter analysis
  26. 26qPCR- make cDNA from tissue
    - Perform PCR in presence of fluorescent dye
    - measure fluorescence after each cycle
  27. 27Promoter analysis (promoter bashing)putative binding sites found by comparison with genes known to bind same TF
    Promoter is bound to a reporter gene so level of reporter gene is a measure of promoter activity
    Construct is altered (deletions) and gene activity measured
  28. 28NO-gaseous
    -free radical
    -half-life = 5-10s
  29. 29NO in CNS-cNOS close to NMDA receptors so it responds to Ca2+ implicating synaptic plasticity
    e.g. glutamate activates receptors which stimulate NO pathway
    NO feedsback to stimulate glutamate production (LTP)
  30. 30NO in immune systemkills bacteria and parasites
    iNOS in inflam. cells uses NO as cytostatic and cytotoxic agent
    When overproduced in lungs and intestine can develop arthritis, asthma, crohns disease
    Role in tumour apoptosis/necrosis
  31. 31NO in vasculatureANS releases ACh which acts on endothelial cells which releases NO causing vasodilation
    inhibits platelet aggregation and vascular SM proliferation (=anti-atherosclerotic)
  32. 32NO ProductionACh creates NOS which forms NO from arginine
    NO binds to guanlyl cycline causing production of cGMP. cGMP produces cGMP dependent protein kinase which leads to myosin light chain phosphatate activating mysosin light chain
  33. 33cNOS- constituitively active
    - Enzyme expression controlled by Ca2+/calmodulin
    - short-lives
    -picomoles of NO
  34. 34nNOS-type of cNOS
    - neural
    - cytosolic
    -found in CNS, ENS, NANC neurons and retina
  35. 35eNOS-type of cNOS
    -endothelial
    -bound at cell membrane
    - expressed in endothelium, osteoblasts, osteoclasts, cardiac myocytes, platelets
  36. 36iNOS- inducible expression, constituitive enzyme activity
    -long-lived effects
    -nanomoles of NO
    - transcriptionally induced in response to pathological material (LPS, IFN-g)
    expressed in macrophages, kupffer cells, neutrophils, fibroblasts, vascular SM, endothelial cells
  37. 37Nitroglycerine100 year old treatment for angina. Breaks down into NO in vivo and causes vasodilation
    (also active component in dynamite)
  38. 38Build up of cGMP is counteracted by.....phosphodiesterase-5
  39. 39Viagrainhibits the activity of phosphodiesterase-5 which means excess cGMP builds up, BVs relax to get increased blood flow
  40. 40Signalling molecules that bind to nuclear receptorssteroid hormones, thyroid hormones, retanoids
  41. 41Nuclear receptorsHeld in inactive state by inhibitory proteins.
    Binding to ligand - confirmational change
    Interact with co-receptors to direct transcription
    DNA binding domain of each receptor contains 2 repeats of c4 zinc fingers
  42. 42DNA response elements bound by homodimerse.g. GRE/ERE - steroid horomes bind as symmetric homodimers on inverted repeat DNA site
    Homodimeric receptors = in cytoplasm in absence of ligand (anchored by inhibitors e.g. hsp90) Translocate to nucleus on binding (lose inhibition)
  43. 43DNA response elements bound by heterodimerse.g. VDRE, TRE, RARE bound by thyroid hormones and retinoid heterodimers (with RXR) to direct repeat sites
    Heteromeric dimers = exclusively in the nucleus. Absence of ligand = HDAC recruited. Presence of a ligand - HAT recruited
  44. 44FLp- DNA recombinase
    - fusion of estrogen LBD to FLP in lab is sufficicent to the recombinase ligand-dependent
  45. 45Early primary response to steroid hormones1-6hrs
    receptor complexes activate primary response genes
    Induced synthesis of a few different proteins
  46. 46Delayed secondary response to steroid hormones6-48hrs
    Primary protein shuts off primary response gene
    Different primary protein turns on secondary response genes

Informações

Descrição
FlashCards sobre Signalling, criado por lucypickles em 05-06-2015.
Criado por
lucypickles
Visualizações
1
Avaliação

Fale Conosco

Sobre o que é sua mensagem?

O que você acha do novo visual?

Você gostou?